A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus.

Trial Profile

A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Retapamulin (Primary) ; Linezolid
  • Indications Impetigo; Methicillin-resistant Staphylococcus aureus infections; Post-traumatic infections
  • Focus Therapeutic Use
  • Sponsors Stiefel Laboratories
  • Most Recent Events

    • 01 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Jul 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 11 Jul 2009 Actual initiation date (1 Apr 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top